All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lymphoma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lymphoma & CLL content recommended for you

EHA 2022

Share:

Jun 8, 2022

X post image

9 Sept 2022

📚 We summarize highlights on the treatment advances for patients with Hodgkin #lymphoma reported at #EHA2022. Read more here 👇
https://t.co/ID5zNBPSvY #lymsm

X post image

8 Aug 2022

📊 A summary of preliminary data from the JACKPOT8 study: a phase I/II study of golidocitinib, a selective JAK1 inhibitor, in R/R peripheral T-cell lymphoma, presented at #EHA2022

👉 https://t.co/bvDq2Ui5iI 👈

#lymsm #lymphoma

X post image

5 Aug 2022

👀 During #EHA2022 Congress, the Lymphoma Hub spoke with @MarekTrnenyDr, @CharlesUniPRG. We asked, Is peripheral neuropathy in patients with #DLBCL more severe after pola-R-CHP vs R-CHOP treatment?

👉 https://t.co/1LcXKQd6cs 👈

#lymsm #lymphoma

X post image

25 Jul 2022

#EHA2022 @DrAnitaKumar discusses #MCL: historic treatments, novel targeted therapies, developments in the relapsed/refractory setting and the SHINE and OAsIs trials

👉 https://t.co/jH0K6yAZow 👈

#lymsm #lymphoma @MSKCancerCenter

X post image

22 Jul 2022

🎥 During #EHA2022, the Lymphoma Hub spoke with @gilles_salles, @MSKCancerCenter. We asked, POLARIX trial: How does MYC and BCL2 expression impact outcomes post frontline treatment with polatuzumab vedotin (PV) in diffuse large B-cell lymphoma (DLBCL)❓
https://t.co/rPSYyLfF3l

X post image

4 Jul 2022

During #EHA2022 , the Lymphoma Hub spoke with @AnnaSureda5, Catalan Institute of Oncology. We asked, What are the key considerations for CAR T-cell therapy in elderly patients with #lymphoma?

👉 https://t.co/kikcV7rSJD 👈

#lymsms

X post image

12 Jun 2022

We hope you’ve enjoyed keeping up with our live #EHA2022 congress updates! 🎓

Keep an eye on our socials for post-congress summaries and key insights! 📲

#EHA2022 #medicalcongress #cancerawareness

X post image

12 Jun 2022

#EHA2022 | Othman Al-Sawaf, @UniCologne, provided updated efficacy and safety data on VEN-Obi in CLL with all patients being off study treatment for ≥ 4 years. PFS remained significantly superior for VenObi vs Clb-Obi (Median-NR vs 36.4 mo) #lymsm #lymphoma

X post image

12 Jun 2022

#EHA2022 | Initial safety and efficacy results of CC-95251 #lymsm

X post image

12 Jun 2022

CONGRESS #EHA2022 | Paolo Strati,
@MDAndersonNews, presents the results with CC-95251, an anti-SIRPα antibody, in combination with rituximab, in heavily pretreated patients with CD20+ NHL. Of note, patients with previous SCT or #CARTcell were eligible #lymsm #lymphoma

X post image

12 Jun 2022

#EHA2022 | Alessandra Ferrajoli investigated chemoimmunotherapy + targeted therapy in CLL. In 45 pts treated, the 5-year PFS and OS were 97.7% and 97.8%, respectively. After a median follow-up of 44.2 mos after discontinuing ibrutinib, 6 pts had an MRD recurrence #lymsm

X post image

12 Jun 2022

#EHA2022 | Won Seog Kim, Samsung Medical Center, considers that the initial clinical activity seen in PTCL with golidocitinib, a JAK1 inhibitor, is very promising. Antibiotic prophylaxis was added after the initial experience with the drug #lymsm #lymphoma

X post image

12 Jun 2022

#EHA2022 | Anthony Mato @MSKCancerCenter presented the phase I/II BRUIN study, investigating BTKi pirtobrutinib in pts with advanced B-cell malignancies with >2 prior therapies. No DLTs were reported and maximum tolerated dose was not reached. Promising efficacy was shown #lymsm

X post image

12 Jun 2022

CONGRESS #EHA2022 | Jean-Marie Michot @GustaveRoussy presents the ph II of ASTX660 in patients with T cell #lymphoma. Lipase increase, already reported in the ph I, was asymptomatic. No radiographic change in the pancreas. 1.3% experienced pancreatitis related to the drug #lymsm

X post image

12 Jun 2022

#EHA2022 | Peter Hillmen @LeedsHospitals presented results from the PHASE III NCRI FLAIR TRIAL, showing a combination of ibrutinib + VEN results in a high rate of MRD negativity in the blood (71.3%) and marrow (65.4%) within 2 years of treatment in untreated CLL #lymphoma #lymsm

X post image

12 Jun 2022

CONGRESS | #EHA2022 | @Mchamuleau, @ScienceLab_MCBI presents first results from multicenter randomized HOVON/SAKK trial in high-risk Burkitt #lymphoma. Data are obtained from 89 patients in a median follow-up of 19 months. Trial is closed prematurely #lymsm #CLL

X post image

12 Jun 2022

CONGRESS #EHA2022 LBA:
Isabelle van Zeventer @umcg, presents the largest study on clonal evolution in the general population. Spliceosome, JAK2 and TP53 are found to be high risk mutations. TET2 and ASXL1 are moderate DNMT3A poses low/no risk #lymsm #mpnsm #allsm #leusm #mmsm

X post image

12 Jun 2022

It's the final day of the 2022 @EHA_Hematology congress! Stay tuned for live coverage of the following sessions:

Chronic lymphocytic leukemia and related disorders - Clinical
Aggressive Non-Hodgkin lymphoma - Clinical

#EHA2022 #medicalcongress #cancerawareness

X post image

12 Jun 2022

CONGRESS | #EHA2022 | LBA: Barbara Eichhorst, @UniCologne presents results from GAIA/CLL13 trial on co-primary endpoint of PFS which was met. Superior PFS at 3 y for both GV-based tx.
- GIV vs CIT: 90.5% vs 75.5%
- GV vs CIT: 87.7% vs 75.5%
- RV vs CIT: not superior #CLL #lymsm

X post image

12 Jun 2022

CONGRESS #EHA2022 | Catherine Thieblemont
@HopSaintLouis presented EPCORE-NHL-1 phase II study results of epcoritamab in pts with R/R LBCL. N=157, median follow-up=10.7 months, ORR=63%, CR=39%, low grade AEs including CRS #lymsm #lymphoma

X post image

11 Jun 2022

CONGRESS #EHA2022 | Daniel Noerenberg
@ChariteBerlin discussed the genetic and epigenetic landscape of PMBCL pathogenesis and its impact on outcomes #lymsm #lymphoma

X post image

11 Jun 2022

CONGRESS #EHA2022 | @AChiappella77 @FondazioneIRCCS presented the final results of FILVERAL 12 phase II study of bortezomib + DHAP in pts with R/R DLBCL. N=107, the primary endpoint was not met #lymsm #lymphoma

X post image

11 Jun 2022

CONGRESS #EHA2022 | Swaminathan Iyer @MDAndersonNews presented first-in-human results of COBALT-LYM phase I trial of CTX130 in heavily pretreated patients with R/R TCL. N=18, CTX130 showed encouraging efficacy and a tolerable safety profile across all DLs #lymsm #lymphoma

X post image

11 Jun 2022

CONGRESS #EHA2022 | Othman Al-Sawaf from the University Hospital of Cologne presented the transcriptomic characterization of MRD response & non-response in pts treated with fixed-duration venetoclax-obinutuzumab. MRD status was strongly correlated with PFS and OS #lymsm #lymphoma

X post image

11 Jun 2022

#EHA2022 | CRS incidence and severity improved significantly with mandatory dex, especially after 1st dose.
Further information on glofitamab's safety profile 👇
#lymphoma #lymsm

X post image

11 Jun 2022

#EHA2022 | Duration of response with glofitamab was led by complete responses. Of note, patients were off therapy at 9 months. In the prior Ph I, durable responses were seen beyond 24 months #lymphoma #lymsm

X post image

11 Jun 2022

CONGRESS #EHA2022 | @mike_dickinson1 presents the latest data of glofitamab, CD20xCD3 bispecific, in patients with r/r DLBCL and a median of 3 PL, including #CARTcell. The primary endpoint was met: fixed-duration treatment led to a 39.4% CR rate #lymphoma #lymsm

X post image

11 Jun 2022

#EHA2022 | Won Seog Kim, Samsung Medical Center presented a phase I/II study investigating anbal-cel, an anti-CD19 CAR-T therapy in R/R LBCL. CR rate, 82%. Of 11 pts, 5 had CRS; 4 were grade 1/2 and one grade 3. One pt dosed at DL3 experienced a grade 2 NE #lymphoma #lymsm

X post image

11 Jun 2022

#EHA2022 | @NGhoshMD, @levinecancer, showed that liso-cel as second-line treatment in patients with LBCL who met ≥ 1 frailty criteria and for whom HSCT was not intended led to durable responses (Median PFS and OS, nr; 6-mo PFS for HL pts, 75%) & no new safety concerns #lymsm

X post image

11 Jun 2022

#EHA2022 | @mike_dickinson1,@PeterMacCC, presented a phase I study on YTB323, an autologous CD19-directed CAR-T cell, in R/R DLBCL. ORR was 69% and responses appeared durable. A total of 10 (36%) pts experienced CRS at DL2, 1 of which was grade 3/4 #lymphoma #lymsm

X post image

11 Jun 2022

#EHA2022 | @AnnaSureda5 presented a subgroup analysis of ZUMA-7. Second line axi-cel vs SOC was associated with superior EFS (HR, 0.276, P<0.0001), and higher CR rates (75% vs 33%). Grade ≥3 TEAEs occurred in 94% and 82% of axi-cel and SOC pts, respectively #lymphoma #lymsm

X post image

11 Jun 2022

#EHA2022 | Pierre Sesques, @CHUdeLyon, addressed modifiable risk factors for toxicity and management of CAR-T toxicity in a real-world population. Grade 3+ CRS, ICANS, or Tocilizumab and corticosteroids use did not have a negative impact on survival #lymphoma #lymsm

X post image

11 Jun 2022

POSTER | #EHA2022 | Ana Jiménez Ubieto et al. validated the use of NGS based MRD quantification in Liquid Biopsies from follicular #lymphoma. Achievement of negative MRD after treatment enhances prognostic information on patient outcome #lymsm #lymphoma

X post image

11 Jun 2022

POSTER | #EHA2022 | Marek Trněný, @CharlesUniPRG et al,. evaluated the impact of Pola-R-CHP vs R-CHOP on peripheral neuropathy. Pola-R-CHP did not result in different rates or severity of PN vs RCHOP. #lymsm #lymphoma

X post image

11 Jun 2022

The Lymphoma Hub will be bringing you live updates during our live coverage of @EHA_Hematology congress!
Today's sessions: Indolent and MCL, Aggressive Lymphoma, Gene therapy and cellular immunotherapy, CLL: Translational research
#EHA2022 #medicalcongress #cancerawareness

X post image

10 Jun 2022

POSTER | #EHA2022 | Franck Morschhauser et al analyzed expression status of BCL2 and MYC, and rearrangements of BCL2, BCL6 and MYC as independent prognostic markers. Multivariate analyses support the benefit of Pola-R-CHP in patients with BCL2+ and MYC+ DLBCL #lymsm #lymphoma

X post image

10 Jun 2022

POSTER | #EHA2022 | Fatma Zehra Eraslan et al. provided data verifying the efficiency of current CNS prophylaxis in preventing CNS relapse in DLBCL. Patients with CNS relapse had poor prognosis (median survival- 2 months) #lymsm #lymphoma

X post image

10 Jun 2022

Congress| #EHA2022 @LNastoupilMD, @EmoryUniversity outlines the CELESTIMO phase 3 trial which evaluates the efficacy and safety of Mosunetuzumab-lenalidomide versus rituximab plus lenalidomide in patients with previously treated R/R FL #lymphoma #lymsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Laurie H. Sehn, @BCCancer discusses whether TAFA + LEN and rituximab provides improved clinical benefit compared with LEN and rituximab in pts with r/r FL or MZL #lymphoma #lymsm #medicalcongress

X post image

10 Jun 2022

#EHA2022 | Luciana Vinti provided results from the KEYNOTE-667 STUDY, investigating pembro plus chemo in patients with ND cHL. Treatment was well tolerated and resulted in 68% of patients having a PET-negative response at end of chemo, and being spared RT #lymsm #lymphoma

X post image

10 Jun 2022

#EHA2022 | An ORR of 56% and 1-year PFS of 42.3% were reported

Most toxicities were grade I and skin related

#lymsm #lymphoma

X post image

10 Jun 2022

#EHA2022 | @BroeckelmannPJ, @UKKoeln, presented an interim analysis of the phase II AERN trial, showing nivolumab and 20Gy RT at a single lesion was well tolerated and led to an abscopal response in 56% of pts previously failing anti-PD1 treatment for R/R HL #lymsm #lymphoma

X post image

10 Jun 2022

#EHA2022 | TEAEs leading to dose interruption or withdrawal occurred in 56.4% and 27.4% of pts, respectively

Immune related TEAEs occurred in 32.5% of pts, eight pts experienced Guillain-Barré syndrome, and 4/8 pts has GBS resolved #lymsm #lymphoma

X post image

10 Jun 2022

#EHA2022 | @ccarlostella, @HumanitasMilano discussed phase II results for camidanlumab tesirine, an antibody-drug conjugate, in pts with R/R CHL.
-> Cami demonstrated an ORR of 70.1% (CR: 33.3%), median DOR of 13.7 mos and median PFS of 9.1 mo #lymsm #lymphoma

X post image

10 Jun 2022

#EHA2022 | A+AVD led to a 32% reduction in the risk of progression compared with ABVD, and fewer second malignancies were reported #lymsm #lymphoma

X post image

10 Jun 2022

#EHA2022 | John Radford, @OfficialUoM, presented phase III data supporting A+AVD as a superior option for previously untreated stage III and IV cHL. There was a 41% reduction in the risk of death with A+AVD vs ABVD, and benefit across prespecified subgroups #lymsm #lymphoma

X post image

10 Jun 2022

Congress| #EHA2022 Lisa J. Croner, @AbbVieUS reports on resistance mutations at the time of PD in pts treated with fixed-duration I+V in the CAPTIVATE trial, highlighting that no resistance mutations in BTK, PLCG2, or BCL2 were identified #lymphoma #lymsm #medicalcongress

X post image

10 Jun 2022

RT @ALL_Hub_: CONGRESS | #EHA2022 | Outcomes from different studies investigating different CAR T cell constructs #lymphoma #lymsm #allsm #…

X post image

10 Jun 2022

RT @ALL_Hub_: CONGRESS | #EHA2022 | @drclaireroddie, @UCL @uclcancer @UCLH gives a talk on different engineering methods in dual targeting…

X post image

10 Jun 2022

RT @ALL_Hub_: CONGRESS | #EHA2022 | He concluded that short- and middle-term toxicity profiles are known enough to training HCPs and specif…

X post image

10 Jun 2022

RT @ALL_Hub_: CONGRESS| #EHA2022 | @Cchabannon, @univamu, on managing CAR T cell toxicities:
- Short-term AEs in different CAR T cells, dif…

X post image

10 Jun 2022

The Lymphoma Hub will be covering the following session/s today virtually (&/or) in-person:

Lymphoma biology and translational research

Stay tuned for live updates, key insights, and interview coverage!

#EHA2022 #medicalcongress #cancerawareness

X post image

7 Jun 2022

The @lymphomahub will be covering the EHA 2022 Congress!

The first ever hybrid @EHA_Hematology congress, where we will be attending online and in Vienna!

Keep an eye on our socials for live updates throughout the day! 🗣💻

#EHA2022 #medicalcongress #cancerawareness

X post image

6 Jun 2022

To help navigate the exciting content being presented at the #EHA2022 Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in #lymphoma and #CLL. Check it out 👇
https://t.co/cS6AVOh97h

pan> </span

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022 European Hematology Association

Your opinion matters

In practice, what is the most common reason you discontinue rituximab maintenance after BR in older patients with previously untreated MCL?

Newsletter

Subscribe to get the best content delivered to your inbox